Holiday layoffs

January 2009
Pharmaceutical Representative;Jan2009, Vol. 39 Issue 1, p9
The article reports on the announcement of layoffs at ImClone Systems Inc. and Sanofi-Aventis. Nearly half of ImClone's sales force will be laid off while Sanofi-Aventis will lay off an unspecified number of sales representatives, perhaps up to 10% of its sales force. Also, Chris Viehbacher was named as the new chief executive officer (CEO) of Sanofi-Aventis. Comments from Sanofi-Aventis spokesman Marc Greene are included.


Related Articles

  • Sanofi and AstraZeneca announce major job cuts. Arnold, Matthew; McGuire, Stephen // Medical Marketing & Media;Feb2005, Vol. 40 Issue 2, p14 

    The article reports that Sanofi-Aventis SA is slashing nearly 700 positions at its U.S. headquarters, including a number of sales and marketing posts on Aventis brands, while AstraZeneca PLC reduces its U.S. contract sales force by 500, around 10 percent of its sales force overall. A...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Jan2008, Vol. 7 Issue 1, p3 

    The article offers news briefs related to developments in the U.S. pharmaceutical industry. ImClone Systems Inc. and Sanofi-Aventis are asked to pay $60 million to Yeda Research and Development Co. as part of their Erbitux patent settlement deal. Novartis has licensed Watson to market the...

  • Cancer News Round-up.  // PharmaWatch: Monthly Review;Oct2008, Vol. 7 Issue 10, p4 

    The article offers news briefs related to the pharmaceutical industry, specifically on cancer announcements. The Japanese Ministry of Health, Labor and Welfare granted an approval for the use of Sanofi-Aventis SA's Taxotere injection in prostate cancer. Celgene Corp.'s Amrubicin received fast...

  • Sanofi-Aventis: linked to biotech acquisitions.  // PharmaWatch: Monthly Review;Nov2006, Vol. 5 Issue 11, p45 

    The article reports on the unsuccessful attempt by France-based drug company Sanofi-Aventis to acquire U.S. biotech firm ImClone Systems Inc. earlier in 2006. The attempted acquisition of ImClone Systems came to light when its third largest shareholder Carl Icahn publicly refused the bid...

  • Sanofi-Aventis layoffs cut total US sales forces to 5,700. B. C. // Medical Marketing & Media;May2010, Vol. 45 Issue 5, p16 

    The article reports on the 400 sales representatives laid off by the Sanofi-Aventis in April 2010.

  • CORPORATE.  // MondayMorning;12/10/2007, Vol. 15 Issue 49, p2 

    The article presents updates related to legal actions in the pharmaceutical industry. ImClone Systems Inc and Sanofi-Aventis SA have settled a patent dispute with Yeda Research and Development Company Ltd. BioCryst Pharmaceuticals Inc. said it is discontinuing a midstage clinical trial for the...

  • CORPORATE.  // MondayMorning;12/8/2008, Vol. 16 Issue 48, p2 

    The article offers news briefs related to pharmaceutical industry in the U.S. in December 2008. France's top drugmaker Sanofi-Aventis SA has planned to reorganize its research and development (R&D) division in the U.S. Health insurer UnitedHealth Group Inc. has raised the lower end of its 2009...

  • Sanofi-aventis to buy Ghattem.  // Chain Drug Review;1/4/2010, Vol. 32 Issue 1, p44 

    The article reports on the decision of French drug company Sanofi-Aventis SA to acquire drug developer Chattem Inc. of Chattanooga, Tennessee.

  • Sanofi makes cuts to field force, consolidates functions. Arnold, Matthew // Medical Marketing & Media;Dec2011, Vol. 46 Issue 12, p15 

    The article reports that Sanofi-Aventis SA will carry further reductions to its U.S. sales force and consolidation of several functions following its acquisition of Genzyme Corp.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics